Valsamma Eapen A. K. Gururaj
Forgot your login? GET HELP
Background: Risperidone is a novel antipsychotic drug that has
been tried in the treatment of several child psychiatric disorders. In an open
clinical study, we evaluated the safety and efficacy of risperidone in children
with developmental disorder and behavioral problems including
attention-deficit/hyperactivity disorder (ADHD).
Method: Twelve patients aged 4 to 14 years who had a
DSM-IV-diagnosed developmental disorder and ADHD in addition to other behavioral
problems, in particular aggression, were treated with risperidone for a period
of up to 2 years with daily doses ranging from 1 to 3 mg. Data were gathered
from December 2002 to December 2004.
Results: A positive clinical response was noted in 9 of the 12
patients within 3 months of study recruitment according to the Clinical Global
Impressions-Improvement scale. Risperidone was well tolerated by all 12
patients. The most commonly reported side effect was sedation, which
necessitated dosage reduction in 2 patients, but not discontinuation.
Conclusions: Our findings suggest that risperidone may be an
effective and safe treatment for children and adolescents with developmental
disorder and disruptive behaviors.
Prim Care Companion J Clin Psychiatry 2005;7(5):221-224
https://doi.org/10.4088/PCC.v07n0502
© Copyright 2005 Physicians Postgraduate Press, Inc.